My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Royalty Pharma plc - Class A Ordinary Shares (NQ:RPRX)

44.83 +0.62 (+1.40%)

Streaming Delayed Price Updated: 2:16 PM EST, Feb 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Royalty Pharma plc - Class A Ordinary Shares

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Jim Cramer Likes This Biotechnology Stock: 'It's Not Big, But It's Not Bad' ↗

October 14, 2022

On CNBC’s "Mad Money Lightning Round," Jim Cramer said he likes Royalty Pharma plc (NASDAQ: RPRX) and will stick with it. "It’s not big, but it’s not bad," he added.

Via Benzinga

Royalty Pharma Announces Expansion of Leadership Team

October 12, 2022

From Royalty Pharma plc

Via GlobeNewswire

Royalty Pharma Announces R&D Funding Collaboration With Merck

October 12, 2022

Novel collaboration structure supports pipeline innovation

From Royalty Pharma plc

Via GlobeNewswire

Theravance Outlines $250M Capital Return Program; To Repurchase GSK's Entire Holdings ↗

September 19, 2022

Via Benzinga

Expert Ratings for Royalty Pharma ↗

August 08, 2022

Within the last quarter, Royalty Pharma (NASDAQ:RPRX) has observed the following analyst ratings:

Via Benzinga

Royalty Pharma: Q2 Earnings Insights ↗

August 04, 2022

Royalty Pharma (NASDAQ:RPRX) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Expert Ratings for Royalty Pharma ↗

June 14, 2022

Royalty Pharma (NASDAQ:RPRX) has observed the following analyst ratings within the last quarter:

Via Benzinga

Royalty Pharma's Return On Capital Employed Insights ↗

August 22, 2022

Pulled from Benzinga Pro data, Royalty Pharma (NASDAQ:RPRX) posted Q2 earnings of $491.60 million, an increase from Q1 of 283.81%. Sales dropped to $535.96 million, a 4.63% decrease between quarters.

Via Benzinga

Warren Buffett's Berkshire Takes Another Bite Of Apple, Boosts Energy Holdings, Cashes Out Of Verizon: What 13F Filing Reveals ↗

August 16, 2022

Warren Buffett-owned Berkshire Hathaway, Inc.’s (NYSE: BRK-A) (NYSE: BRK-B) portfolio saw some noteworthy and a few other nominal changes in the second quarter, according to the company's 13F filing.

Via Benzinga

Jim Cramer Shares His Takes On First Solar, Royalty Pharma And More ↗

August 11, 2022

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Royalty Pharma PLC (NASDAQ: RPRX) is going higher. "Hold on to it."

Via Benzinga

The Daily Biotech Pulse: Much Awaited FDA Nod For Novavax's COVID-19 Shot, DSMB Suggests ContraFect To Stop Antimicrobial-Resistant Infection Study, CytomX Restructures ↗

July 14, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Executives Sell Around $325M Of 3 Stocks ↗

May 24, 2022

Gold futures traded higher this morning on Tuesday. Investors, meanwhile, focused on some notable insider trades.

Via Benzinga

Expert Ratings for Royalty Pharma ↗

May 13, 2022

Analysts have provided the following ratings for Royalty Pharma (NASDAQ:RPRX) within the last quarter:

Via Benzinga

Theravance Biopharma, Innoviva Gain On Selling TRELEGY ELLIPTA Royalty Interests ↗

July 13, 2022

Via Benzinga

Warren Buffett Stocks: Royalty Pharma plc ↗

July 08, 2022

As of March 31st, 2022, Buffett’s Berkshire Hathaway owned about 1.5 million shares of Royalty Pharma plc for a market value of $58.3 million. Let's analyze the healthcare company in greater detail.

Via Talk Markets

This Analyst Thinks Blueprint Medicines' Non-Dilutive Funding 'Deflates M&A Speculation' ↗

June 30, 2022

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2022 ↗

June 14, 2022

Upgrades

Via Benzinga

Royalty Pharma: Q1 Earnings Insights ↗

May 05, 2022

Royalty Pharma (NASDAQ:RPRX) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Recap: Royalty Pharma Q1 Earnings ↗

May 05, 2022

Royalty Pharma (NASDAQ:RPRX) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Management of Technology Companies Continue Selling - Zillow (Z) ↗

May 31, 2022

In a week where we saw most market indices rebound sharply, insiders scaled back their buying after three weeks of elevated buying. Buying declined by 64% in absolute dollar terms and 26% in terms of...

Via Benzinga

Royalty Pharma Earnings Perspective: Return On Capital Employed ↗

May 27, 2022

Pulled from Benzinga Pro data, Royalty Pharma (NASDAQ:RPRX) posted Q1 earnings of $128.08 million, an increase from Q4 of 138.64%. Sales dropped to $562.00 million, a 2.43% decrease between quarters.

Via Benzinga

Warren Buffett Stocks: Berkshire Hathaway Goes On Offense In Stock Market, Adds More Apple ↗

May 16, 2022

Buffett's Berkshire added to Apple and Chevron during the Q1 sell-off. More details to come.

Via Investor's Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For May 13, 2022 ↗

May 13, 2022

Upgrades

Via Benzinga

How To Attend Royalty Pharma Q1 2022 Earnings Conference Call ↗

May 03, 2022

Royalty Pharma (NASDAQ:RPRX) will host a conference call at 08:00 AM ET on May 5, 2022, to discuss Q1 2022 earnings results. How to Attend Royalty Pharma (RPRX) Conference Call Follow this link to...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2022 ↗

April 14, 2022

Upgrades

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022 ↗

April 06, 2022

Upgrades

Via Benzinga

Expedia And 3 Other Stocks Insiders Are Selling ↗

March 31, 2022

Although gold futures traded lower on Thursday, there were a few notable insider trades. When insiders sell shares, it indicates their concern in the company’s prospects or...

Via Benzinga

Hopeful Golden Cross Forms On Royalty Pharma's Chart ↗

March 01, 2022

If history is any guide, there may be good fortune ahead for shares of Royalty Pharma (NASDAQ:RPRX). A so-called "golden cross" has formed on its chart and, not surprisingly,...

Via Benzinga

Looking Into Royalty Pharma's Return On Capital Employed ↗

February 16, 2022

According to Benzinga Pro, during Q4, Royalty Pharma (NASDAQ:RPRX) earned $53.67 million, a 75.8% increase from the preceding quarter. Royalty Pharma's sales decreased to $576.00 million, a 1.67%...

Via Benzinga

The Daily Biotech Pulse: Larimar Plunges On Extension Of Clinical Hold, ImmunityBio Gains On Positive Data, Adcom Test Awaits Avenue Therapeutics ↗

February 15, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus ImmunityBio Says Cancer Combo Therapy Produces Positive Results In Late-Stage...

Via Benzinga

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.